Thanks:
0
Likes:
0
Dislikes:
0
-
Scancell Holdings Plc (‘Scancell’ or the ‘Company’) Clinical Trial Approval for SCIB1
Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee (‘GTAC’) and by the Medicines and Healthcare products Regulatory Agency (‘MHRA’) Medicines Division. In addition, Scancell’s US partner Ichor Medical Systems (‘Ichor’) has obtained the required parallel approval from the MHRA Devices Division for the use of Ichor’s TriGrid™ electroporation delivery device to administer SCIB1 to patients participating in
More...
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
Bookmarks